Myosteatosis

There are 36 papers on myosteatosis in aging research: 1 trial and 24 observational studies in people, 11 reviews. The newest story, Nov 9, 2026: “Heart scan measures linked to wider gaps in cardiovascular risk”.

Biomarker

36 papers study it184 more mention it35 findings

18 new papers in 30 daysSee all 220 papers on myosteatosis

“After full adjustment, associations remained significant for HF (1.93 [1.31–2.82])”
AI-driven Measurement of Myosteatosis in Coronary Artery Calcium Scans Predicts Atrial Fibrillation and Heart Failure. An AI-CVD Study within the Multi-Ethnic Study of Atherosclerosis (MESA)AHA Scientific Sessions 2025 abstract2025doi:10.1161/circ.152.suppl_3.4369683
  • Human trial1
  • Humans24

Effects

7

Physical function

downin humans1

1 study
  1. Myosteatosis impairs physical function in humans.

    “differentially associated with clinically meaningful age-related outcomes, including changes to gait, balance, muscle strength, and physical function.”

    Review

    Myosteatosis: an emerging biomarker of aging

    Frontiers in aging

Cancer

no changein humans1

1 study
  1. Myosteatosis was not clearly linked with cancer in humans (Liver transplant recipients; no significant difference by myosteatosis status).

    “Notably, cardiovascular disease, diabetes mellitus, and malignancy did not differ significantly by myosteatosis status.”

    HumansLiver transplant recipients; no significant difference by myosteatosis statusn = 503

    Myosteatosis as a prognostic biomarker for post-transplant survival and cardiometabolic outcomes: A retrospective study

    Canadian liver journal

More on Cancer

Diabetes mellitus

no changein humans1

1 study
  1. Myosteatosis was not clearly linked with diabetes mellitus in humans (Liver transplant recipients; no significant difference by myosteatosis status).

    “Notably, cardiovascular disease, diabetes mellitus, and malignancy did not differ significantly by myosteatosis status.”

    HumansLiver transplant recipients; no significant difference by myosteatosis statusn = 503

    Myosteatosis as a prognostic biomarker for post-transplant survival and cardiometabolic outcomes: A retrospective study

    Canadian liver journal

More on Diabetes mellitus

Cardiovascular disease

no changein humans1

1 study
  1. Myosteatosis was not clearly linked with cardiovascular disease in humans (Liver transplant recipients; no significant difference by myosteatosis status).

    “Notably, cardiovascular disease, diabetes mellitus, and malignancy did not differ significantly by myosteatosis status.”

    HumansLiver transplant recipients; no significant difference by myosteatosis statusn = 503

    Myosteatosis as a prognostic biomarker for post-transplant survival and cardiometabolic outcomes: A retrospective study

    Canadian liver journal

More on Cardiovascular disease

Inflammation

upin humans1

1 study
  1. Myosteatosis increases inflammation in humans.

    “Myosteatosis induces proinflammatory changes that contribute to decreased muscle function, compromise mitochondrial function, and increase inflammatory response in muscles.”

    Reviewskeletal muscle

    Myosteatosis: diagnostic significance and assessment by imaging approaches

    Quantitative imaging in medicine and surgery

More on Inflammation

STRENGTH

downin humans1

1 study
  1. Myosteatosis impairs strength in humans.

    “it exhibits a negative correlation with muscle mass, strength, and mobility representing a contributing factor to decreased muscle quality”

    Reviewskeletal muscle

    Myosteatosis: diagnostic significance and assessment by imaging approaches

    Quantitative imaging in medicine and surgery

Survival

downin humans1

1 study
  1. Myosteatosis is linked with lower survival in patients with liver cirrhosis.

    “Patients with myosteatosis exhibited lower 360-day survival (log-rank p = 0.001) compared to those without it.”

    Humansin patients with liver cirrhosisn = 197

    The Presence of Myosteatosis Is Associated with Age, Severity of Liver Disease and Poor Outcome and May Represent a Prodromal Phase of Sarcopenia in Patients with Liver Cirrhosis

    Journal of clinical medicine

Upstream

1

Chronological age

upin humans1

1 study
  1. Chronological age increases myosteatosis in humans.

    “Myosteatosis consistently increased with age, independent of weight change”

    Review

    Myosteatosis: an emerging biomarker of aging

    Frontiers in aging

Associations

19

Mortality

upin humans9HR 1.5–3.83

9 studies
  1. Myosteatosis is linked with a higher risk of mortality in humans after TAVR (HR 3.83, 95% CI 1.54-9.53).

    “Myosteatosis was associated with higher risks of both MACE (HR: 2.39, 95% CI: 1.13-5.05, P = 0.023) and all-cause mortality (HR: 3.83, 95% CI: 1.54-9.53, P = 0.004).”

    Humansafter TAVRn = 371

    Prognostic role of myosteatosis in predicting MACE and mortality after TAVR: insights from CT-based body composition analysis

    The journal of nutrition, health & aging

  2. Myosteatosis predicts mortality in humans (Liver transplant recipients) (HR 1.50, 95% CI 1.06–2.12).

    “myosteatosis independently predicted both all-cause mortality (HR 1.50 [95% CI 1.06-2.12]; p = 0.024)”

    HumansLiver transplant recipients75.9% malesn = 503

    Myosteatosis as a prognostic biomarker for post-transplant survival and cardiometabolic outcomes: A retrospective study

    Canadian liver journal

  3. Myosteatosis is linked with a higher risk of mortality in humans after liver transplantation for HCC; multivariable Cox model (HR=3.182, p=0.0001).

    “myosteatosis (HR=3.182, p=0.0001)”

    Humansafter liver transplantation for HCC; multivariable Cox modelskeletal muscle

    Novel opportunistic imaging biomarkers with AI-assisted sarcopenia assessment associated with survival after liver transplantation for hepatocellular carcinoma

    Revista espanola de enfermedades digestivas

  4. Myosteatosis predicts mortality in humans (myosteatosis above 15% at T12 on CT; 12-month follow-up) (HR 3.13; 95% CI 1.01-9.70; survival 78.1% vs 96.6%).

    “The presence of myosteatosis > 15% in T12-CT was an independent predictor of 12-month mortality (HR = 3.13; 95% CI: 1.01-9.70; p = 0.049)”

    Humansmyosteatosis above 15% at T12 on CT; 12-month follow-upskeletal muscle12 months

    The Nutritional Phenotyping of Idiopathic Pulmonary Fibrosis Through Morphofunctional Assessment: A Bicentric Cross-Sectional Case-Control Study

    Life (Basel, Switzerland)

  5. Myosteatosis is linked with a higher risk of mortality in humans (chronic kidney disease stages 3-5).

    “higher %IMAT and lower attenuation were associated with a higher mortality risk”

    Humanschronic kidney disease stages 3-5n = 216

    Myosteatosis is associated with adiposity, metabolic derangements and mortality in patients with chronic kidney disease

    European journal of clinical nutrition

  6. Myosteatosis predicts mortality in humans (older adults undergoing chemotherapy) (aHR = 2.14, 95%CI = 1.07-4.30, p = 0.032).

    “myosteatosis alone (aHR = 2.14, 95%CI = 1.07-4.30, p = 0.032)”

    Humansolder adults undergoing chemotherapyn = 115

    The Role of Frailty and Myosteatosis in Predicting All-Cause Mortality in Older Adults with Cancer

    Current oncology (Toronto, Ont.)

  7. Myosteatosis is associated with mortality in humans.

    “Low skeletal muscle index and myosteatosis were independently associated with increased 90-day mortality.”

    Humans90-daysn = 204

    Low Skeletal Muscle Index And Myosteatosis As Predictors of Mortality In Critically Ill Surgical Patients

    Research SquarePreprint

  8. Myosteatosis raises the risk of mortality in humans (kidney transplant recipients) (HR = 1.82, 95% CI: 1.24-2.67).

    “Recipients with myosteatosis also demonstrated a significantly increased risk of mortality (HR = 1.82, 95% CI: 1.24-2.67, I2 = 7%)”

    Reviewkidney transplant recipientsn = 2,764

    Associations of Low Muscle Mass and Myosteatosis With Kidney Transplant Outcomes: A Systematic Review and Meta-Analysis

    Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation

  9. Myosteatosis is associated with mortality in humans.

    “Myosteatosis has emerged as an important concept in muscle health as it is associated with an increased risk of adverse health outcomes, a higher rate of complications, and increased mortality”

    Reviewassociated with ageing, chronic systemic and neuromuscular diseases, cancer, metabolic syndromes, degenerative events, and trauma

    Myosteatosis: diagnostic significance and assessment by imaging approaches

    Quantitative imaging in medicine and surgery

Muscle stiffness

upin humans1

1 study
  1. Myosteatosis is associated with muscle stiffness in humans (elderly patients).

    “The muscle stiffness was increased in patients with diabetes and with high myosteatosis.”

    Humanselderly patientsskeletal musclen = 20

    09 | The diagnosis of sarcopenia in elderly patients: role of ultrasound and sonoelastography

    Geriatric Care

More on Muscle stiffness

Major adverse cardiac events

upin humans1HR 2.39

1 study
  1. Myosteatosis is linked with a higher risk of major adverse cardiac events in humans after TAVR (HR 2.39, 95% CI 1.13-5.05).

    “Myosteatosis was associated with higher risks of both MACE (HR: 2.39, 95% CI: 1.13-5.05, P = 0.023) and all-cause mortality (HR: 3.83, 95% CI: 1.54-9.53, P = 0.004).”

    Humansafter TAVRn = 371

    Prognostic role of myosteatosis in predicting MACE and mortality after TAVR: insights from CT-based body composition analysis

    The journal of nutrition, health & aging

Metabolic dysfunction-associated steatotic liver disease

upin humans1HR 2.25

1 study
  1. Myosteatosis predicts metabolic dysfunction-associated steatotic liver disease in humans (Post-transplant incidence in liver transplant recipients) (HR 2.25, 95% CI 1.28–3.98).

    “the incidence of post-transplant metabolic dysfunction-associated steatotic liver disease (MASLD) (hazard ratio [HR] 2.25 [95% CI 1.28-3.98]; p = 0.0051)”

    HumansPost-transplant incidence in liver transplant recipientsliver75.9% malesn = 503

    Myosteatosis as a prognostic biomarker for post-transplant survival and cardiometabolic outcomes: A retrospective study

    Canadian liver journal

More on Metabolic dysfunction-associated steatotic liver disease

Cardiovascular disease

upin humans1HR 1.75

1 study
  1. Myosteatosis is linked with a higher risk of cardiovascular disease in humans after full adjustment (HR 1.75 (95% CI 1.29–2.39)).

    “and for AF (1.69 [1.17–2.45]) and total CVD (1.75 [1.29–2.39]) in females.”

    Humansafter full adjustmentthoracic skeletal muscle15 yearsfemalesn = 5,489

    AI-driven Measurement of Myosteatosis in Coronary Artery Calcium Scans Predicts Atrial Fibrillation and Heart Failure. An AI-CVD Study within the Multi-Ethnic Study of Atherosclerosis (MESA)

    AHA Scientific Sessions 2025 abstract

More on Cardiovascular disease

Atrial fibrillation

upin humans1HR 1.78

1 study
  1. Myosteatosis is linked with a higher risk of atrial fibrillation in humans after full adjustment (HR 1.78 (95% CI 1.26–2.50)).

    “After full adjustment, associations remained significant for HF (1.93 [1.31–2.82]), AF (1.78 [1.26–2.50])”

    Humansafter full adjustmentthoracic skeletal muscle15 yearsmalesn = 5,489

    AI-driven Measurement of Myosteatosis in Coronary Artery Calcium Scans Predicts Atrial Fibrillation and Heart Failure. An AI-CVD Study within the Multi-Ethnic Study of Atherosclerosis (MESA)

    AHA Scientific Sessions 2025 abstract

More on Atrial fibrillation

Heart failure

upin humans1HR 1.93

1 study
  1. Myosteatosis is linked with a higher risk of heart failure in humans after full adjustment (HR 1.93 (95% CI 1.31–2.82)).

    “After full adjustment, associations remained significant for HF (1.93 [1.31–2.82])”

    Humansafter full adjustmentthoracic skeletal muscle15 yearsmalesn = 5,489

    AI-driven Measurement of Myosteatosis in Coronary Artery Calcium Scans Predicts Atrial Fibrillation and Heart Failure. An AI-CVD Study within the Multi-Ethnic Study of Atherosclerosis (MESA)

    AHA Scientific Sessions 2025 abstract

More on Heart failure

Chronic obstructive pulmonary disease

upin humans1HR 1.32

1 study
  1. Myosteatosis predicts chronic obstructive pulmonary disease in humans (free of clinical cardiovascular disease at baseline) (HR 1.32).

    “In fully adjusted models, the association remained significant with a hazard ratio of 1.32.”

    Humansfree of clinical cardiovascular disease at baseline15 years

    Artificial Intelligence-Derived Myosteatosis on Coronary Artery Calcium CT Scans Predicts Incident COPD: An AI-CVD Study within the Multi-Ethnic Study of Atherosclerosis (MESA)

    AHA Scientific Sessions 2025 abstract

More on Chronic obstructive pulmonary disease

Graft loss

upin humans1HR 1.99

1 study
  1. Myosteatosis raises the risk of graft loss in humans (kidney transplant recipients) (HR = 1.99, 95% CI: 1.21-3.26).

    “and graft loss (HR = 1.99, 95% CI: 1.21-3.26, I2 = 0%).”

    Reviewkidney transplant recipientsn = 2,764

    Associations of Low Muscle Mass and Myosteatosis With Kidney Transplant Outcomes: A Systematic Review and Meta-Analysis

    Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation

Sarcopenia

upin humans1+55% sarcopenic patients with available ct

1 study
  1. Sarcopenia is associated with myosteatosis in humans (55% of sarcopenic patients with available CT).

    “A total of 55% of sarcopenic patients with available CT also had myosteatosis”

    Humansskeletal muscle

    The Nutritional Phenotyping of Idiopathic Pulmonary Fibrosis Through Morphofunctional Assessment: A Bicentric Cross-Sectional Case-Control Study

    Life (Basel, Switzerland)

More on Sarcopenia

All 19

Funding

6 grants since 2018

US Department of Veterans AffairsJapan Society for the Promotion of Science¥13.9MNational Institute on Aging$4.9M

Latest

Dec 2025: 9Jan 2026: 8Feb 2026: 3Mar 2026: 5Apr 2026: 6May 2026: 8Jun 2026: 11Jul 2026: 8Aug 2026: 1Sep 2026: 8Oct 2026: 10Nov 2026: 986 papers in 12 months
AHA Scientific Sessions 2026 Abstract

Heart scan measures linked to wider gaps in cardiovascular risk

Over a median 12.6 years, cardiovascular disease incidence was 8.7% among people with no counted scan abnormalities versus 11.3% among those without counted conventional…Over a median 12.6 years, cardiovascular disease incidence was 8.7% among people with no counted scan abnormalities versus 11.3% among those without counted conventional risk factors.

Environmental Research

Arsenic metabolism linked to muscle size and fat in adults

A 5% increase in the urinary share of one substance formed from arsenic was linked to 1.62 square centimeters less abdominal muscle area.A 5% increase in the urinary share of one substance formed from arsenic was linked to 1.62 square centimeters less abdominal muscle area.

Cross-sectional · 1,597 peopleMuscle

See all 220 papers on myosteatosis